Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Chemotherapy-induced Nausea and Vomiting (CINV) Clinical Trial

Official title:
A Phase III, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Safety, Tolerability and Efficacy of MK0869/Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With High-Dose Cisplatin

Status Completed

Clinical Trial Summary

This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00952341
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 3
Start date	August 25, 2009
Completion date	May 5, 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01594749` - Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)	Phase 3
Not yet recruiting	`NCT04912271` - Granisetron Transdermal Patch for Prophylaxis of Delayed CINV	Phase 3
Active, not recruiting	`NCT05434663` - Safety Study of Repeat Doses of SUSTOL in Adults	Phase 4
Recruiting	`NCT04472143` - Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents	Phase 2
Completed	`NCT00619359` - Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)	Phase 3
Completed	`NCT03204279` - PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting	Phase 2
Completed	`NCT01111851` - Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)	Phase 1